A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Lymphoma
Interventions: DRUG: DS-3078a
Sponsor: Daiichi Sankyo